由于11％的临床研究遗址未能注册单人患者，37％的招生网站，可以显而易见的是提高效率。涉及较少网站的研究有可能改善这种性能，利用每个治疗区域的最佳领导者，降低旅行和行政成本，并对更容易启动进行调整过程。
此洞察简要介绍了IQVIA对患者和现场订婚的创新方法，例如开创早期规划，创新伙伴关系，新技术和通信工具，与患者倡导团体，精密入学和IQVIA Infosario网关平台一起工作。
介绍
Some 11% of research sites industry-wide fail to enroll a single patient, with 37% of sites under-enrolling, creating inefficiency and lost productivity.1 This represents a waste of time and money benefiting neither sponsors nor other research stakeholders. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier start-up.
涉及较少网站的研究具有提高临床试验效率的承诺，借鉴治疗专家的专业知识，最大限度地减少成本和优化工艺，以便更容易启动。
Early planning is a major factor in trial success – including identifying patient pathways in each country, understanding patient and investigator perspectives, and applying these insights to trial design and implementation. Patient advocacy groups are an important source of information about patient preferences, helping inform study design and tailored communication programs and flag potential enrollment and retention risks. For rare conditions, online sources of patient-generated content can also be mined using social listening tools to help understand how patients experience a particular condition. Early engagement with sites, clinical and medical teams, and in-country regulatory specialists is also critical to successful enrollment planning.
This insight brief examines new and innovative solutions to get drugs to patients faster, via improved patient and site engagement.